IP Library Granted Patent US 7,700,130
Granted Patent B2
US 7,700,130 · App. 11/809,662 · Granted Apr 20, 2010

Preservation of bioactive materials by spray drying

Assignee: MedImmune LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,130
App. No.
11/809,662
Granted
Apr 20, 2010
Kind
B2
Abstract

This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.

Claims (22)

1. A mixture of a suspension or solution with a high pressure gas comprising a pressure ranging from about 250 psi to a pressure less than 90% of a critical pressure of the gas, the suspension or solution comprising a bioactive material, a polyol, a polymer, and a surfactant.

2. The mixture of claim 1 , wherein the bioactive material is selected from the group consisting of proteins, peptides, nucleic acids, bacteria, cells, antibodies, enzymes, serums, vaccines, liposomes, and viruses.

3. The mixture of claim 2 , wherein the viruses are selected from the list consisting of influenza virus, parainfluenza virus, respiratory syncytial virus, herpes simplex virus, cytomegalo virus, SARS virus, corona virus family members, human metapneumovirus, and Epstein-Bar virus.

4. The mixture of claim 3 , wherein the virus is a live virus present in the suspension or solution in a titer ranging from about 10 1 TCID 50 to about 10 12 TCID 50 .

5. The mixture of claim 1 , wherein the bioactive material is present in an amount ranging from about 0.05 weight percent to about 1 weight percent of the suspension or solution.

6. The mixture of claim 1 , wherein the polyol is selected from the group consisting of trehalose, sucrose, sorbose, melezitose, glycerol, fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, palactose, glucose, mannitol, xylitol, erythritol, threitol, sorbitol, and raffinose.

7. The mixture of claim 6 , wherein the polyol is present in an amount ranging from about 1 weight percent to about 40 weight percent of the suspension or solution.

8. The mixture of claim 6 , wherein the polyol is sucrose present in an amount of about 10 weight percent of the suspension or solution.

9. The mixture of claim 6 , further comprising one or more amino acids.

10. The mixture of claim 1 , wherein the polymer is selected from the group consisting of starch, oxidized starch, carboxymethyl starch, hydroxyethyl starch (HES), hydrolyzed gelatin, polyvinyl pyrrolidone, unhydrolyzed gelatin, ovalbumin, collagen, chondroitin sulfate, a sialated polysaccharide, actin, myosin, microtubules, dynein, kinetin, and human serum albumin.

11. The mixture of claim 10 , wherein the polymer has a molecular weight ranging from about 100 kDa to about 300 kDa.

12. The mixture of claim 10 , wherein the polymer is present in a concentration ranging from about 0.5 weight percent to about 10 weight percent of the suspension or solution.

13. The mixture of claim 12 , wherein the polymer comprises HES present in a concentration of about 5 weight percent.

14. The mixture of claim 1 , wherein the surfactant is a nonionic surfactant selected from the group consisting of alkylphenyl alkoxylates, alcohol alkoxylates, fatty amine alkoxylates, polyoxyethylene glycerol fatty acid esters, castor oil alkoxylates, fatty acid alkoxylates, fatty acid amide alkoxylates, fatty acid polydiethanolamides, lanolin ethoxylates, fatty acid polyglycol esters, isotridecyl alcohol, fatty acid amides, methylcellulose, fatty acid esters, silicone oils, alkyl polyglycosides, glycerol fatty acid esters, polyethylene glycol, polypropylene glycol, polyethylene glycol/polypropylene glycol block copolymers, polyethylene glycol alkyl ethers, polypropylene glycol alkyl ethers, polyethylene glycol/polypropylene glycol ether block copolymers, polyethylene glycol sorbitan monolaurate, and polyoxyethylenesorbitan monooleate.

15. The mixture of claim 1 , wherein the surfactant is an ionic surfactant selected from the group consisting of alkylarylsulfonates, phenylsulfonates, alkyl sulfates, alkyl sulfonates, alkyl ether sulfates, alkyl aryl ether sulfates, alkyl polyglycol ether phosphates, polyaryl phenyl ether phosphates, alkylsulfosuccinates, olefin sulfonates, paraffin sulfonates, petroleum sulfonates, taurides, sarcosides, fatty acids, alkylnaphthalenesulfonic acids, naphthalenesulfonic acids, lignosulfonic acids, condensates of sulfonated naphthalenes with formaldehyde, condensates of sulfonated naphthalenes with formaldehyde and phenol, lignin-sulfite waste liquor, alkyl phosphates, quatemary ammonium compounds, amine oxides, and betaines.

16. The mixture of claim 1 , wherein the surfactant is present in an amount ranging from about 0.001 weight percent to about 5 weight percent.

17. The mixture of claim 16 , wherein the surfactant is present in an amount ranging from about 0.01 weight percent to about 1 weight percent.

18. The mixture of claim 1 , wherein the suspension or solution further comprises a buffer comprising a pH from about pH 3 to about pH 8.

19. The mixture of claim 18 , wherein the buffer comprises a phosphate salt, an amino acid, a carbonate salt, a borate salt, an acetate salt, histidine, glycine, or a citrate salt.

20. The mixture of claim 18 , wherein the buffer is present at a concentration ranging from about 2 mM to about 500 mM.

21. The mixture of claim 1 , wherein the suspension or solution further comprises a carrier, excipient, or stabilizer.

22. The mixture of claim 1 , wherein the bioactive material comprises influenza virus, the polyol comprises sucrose, the polymer comprises HES, and the surfactant comprises a block copolymer of polyethylene and polypropylene glycol.

Assignments (2)
CHANGE OF NAME Recorded May 8, 2009
From: MEDIMMUNE VACCINES, INC.
To: MEDIMMUNE, INC.
Reel/Frame 022660/0200 →
CHANGE OF NAME Recorded May 8, 2009
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 022661/0230 →
Continuity (4)
Division 1041265100 · Apr 10, 2003
Provisional Application 6044768300 · Feb 14, 2003
Provisional Application 6037219200 · Apr 11, 2002
Related Publication 20070259334A1 · Nov 8, 2007